Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread

Hung Chih Hsu, Kuo Cheng Huang, Wei-Shone Chen, Jeng Kai Jiang, Shung-Haur Yang, Huann Sheng Wang, Shih-Ching Chang, Yuan Tzu Lan, Chun Chi Lin, Hung Hsin Lin, Sheng Chieh Huang, Hou Hsuan Cheng, Tsai Sheng Yang, Chien Chih Chen, Yee Chao, Hao Wei Teng*

*此作品的通信作者

研究成果: Article同行評審

3 引文 斯高帕斯(Scopus)

指紋

深入研究「Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread」主題。共同形成了獨特的指紋。

Medicine & Life Sciences